Induction of long-term tolerance to a specific antigen using anti-CD3 lipid nanoparticles following gene therapy
Development of factor VIII (FVIII) inhibitors is a serious complication in the treatment of hemophilia A (HemA) patients. In clinical trials, anti-CD3 antibody therapy effectively modulates the immune response of allograft rejection or autoimmune diseases without eliciting major adverse effects. In...
Bewaard in:
| Hoofdauteurs: | , , , , , , |
|---|---|
| Formaat: | Boek |
| Gepubliceerd in: |
Elsevier,
2023-12-01T00:00:00Z.
|
| Onderwerpen: | |
| Online toegang: | Connect to this object online. |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Internet
Connect to this object online.3rd Floor Main Library
| Plaatsingsnummer: |
A1234.567 |
|---|---|
| Kopie 1 | Beschikbaar |